BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 12, 2009
 |  BioCentury  |  Emerging Company Profile

Anaphore: Narrowing the focus

Anaphore Inc. was founded in late 2007 to commercialize a protein engineering platform that had been the basis of now defunct Borean Pharma A/S. Anaphore believes focusing on specific products against a few carefully selected targets will help it succeed where Borean did not. Last week, the newco completed a $25 million series A round to take its first product into the clinic.

The technology, which Anaphore has named TrimerX, is based on the human protein tetranectin, a trimeric plasminogen-binding protein whose three binding domains each contain five loops. By altering the amino acid sequence of these loops, Borean had developed a library of antibody analogs containing specific binders to virtually any target (see BioCentury, Sept. 27, 2004).

Anaphore calls the resulting proteins Atrimers.

"With these kinds of platforms, product selection and target selection are key to success. We saw an opportunity for immune-mediated diseases that wasn't being exploited"...

Read the full 739 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >